Currently, there are 1.77B common shares owned by the public and among those 1.75B shares have been available to trade.
The company’s stock has a 5-day price change of 4.76% and -10.89% over the past three months. CVX shares are trading -3.27% year to date (YTD), with the 12-month market performance down to -14.35% lower. It has a 12-month low price of $132.04 and touched a high of $168.96 over the same period. CVX has an average intraday trading volume of 9.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.17%, -8.05%, and -7.60% respectively.
Institutional ownership of Chevron Corp (NYSE: CVX) shares accounts for 77.48% of the company’s 1.77B shares outstanding.
It has a market capitalization of $244.72B and a beta (3y monthly) value of 0.81. The stock’s trailing 12-month PE ratio is 14.45, while the earnings-per-share (ttm) stands at $9.70. The company has a PEG of 1.79 and a Quick Ratio of 0.83 with the debt-to-equity ratio at 0.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.83% over the week and 3.48% over the month.
Analysts forecast that Chevron Corp (CVX) will achieve an EPS of 2.15 for the current quarter, 1.92 for the next quarter and 10.28 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.98 while analysts give the company a high EPS estimate of 1.98. Comparatively, EPS for the current quarter was 2.93 a year ago. Earnings per share for the fiscal year are expected to decrease by -14.56%, and 23.27% over the next financial year. EPS should shrink at an annualized rate of 8.09% over the next five years, compared to 44.50% over the past 5-year period.
Looking at the support for the CVX, a number of firms have released research notes about the stock. Redburn Atlantic stated their Sell rating for the stock in a research note on April 23, 2025, with the firm’s price target at $124. Barclays coverage for the Chevron Corp (CVX) stock in a research note released on April 23, 2025 offered a Equal Weight rating with a price target of $152. Exane BNP Paribas was of a view on April 15, 2025 that the stock is Neutral, while Scotiabank gave the stock Sector Perform rating on April 11, 2025, issuing a price target of $143. Citigroup on their part issued Buy rating on November 26, 2024.
